Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919665 | 0.80 | KDM1A (0.42) | CA9CA12CA1ERN1AKR1B1 | |
| SCHEMBL4691914 | 0.79 | TAAR1 (0.39) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL31167142 | 0.79 | TAAR1 (0.39) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL6553272 | 0.77 | KDM1A (0.41) | CA9CA12CA1ERN1AKR1B1 | |
| SCHEMBL24724647 | 0.75 | PTGS1 (0.38) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL31088800 | 0.75 | PTGS1 (0.38) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL21979280 | 0.75 | CA9 (0.36) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL25205090 | 0.75 | HSD17B10 (0.41) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL5513552 | 0.75 | ERN1 (0.52) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL1144151 | 0.74 | CA9 (0.44) | CA9CA3CA6CA5ACA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478199-A | Bimetallic catalyst and preparation method thereof, and preparation method of high molecular weight olefin polymer | 万华化学集团股份有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12492187-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-2774917-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | Ajinomoto Co., Inc. (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-2638040-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7045545-B1 | Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists | ELI LILLY AND COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-6881733-B1 | Serotonergic benzofurans | ELI LILLY AND COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| CN-1407982-A | Serotonergic benzofurans | LILLY CO ELI (US) | 2003-04-02 | — | — | CN | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | CA9 1254/4885CA3 2614/4885CA6 2024/4885 |
| US-12492187-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | CA9 378/4885CA3 3441/4885CA6 1148/4885 |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | CA9 3870/4885CA3 938/4885CA6 3155/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA9 1363/4885CA3 3397/4885CA6 3264/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CA9 1363/4885CA3 3397/4885CA6 3264/4885 |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | CA9 1254/4885CA3 2614/4885CA6 2024/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | CA9 2697/4885CA3 1138/4885CA6 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.